Unraveling Cancer Cell Survival and Drug Resistance through Reciprocal Regulation of Epitranscriptome and Non-coding RNA
Background
In recent cancer research, two key mechanisms regulating gene expression have gained prominence: long non-coding RNAs (lncRNAs) and N6-methyladenosine (m6A) RNA methylation. LncRNAs are molecules that do not encode proteins but precisely control gene expression. m6A refers to the chemical modification of RNA molecules by the addition of a methyl group, which determines the fate of genetic information after transcription. These mechanisms, which are core elements of the epitranscriptome, were previously studied as independent regulatory factors. However, studying only individual regulatory mechanisms has limitations in fully elucidating the complex cancer cell survival network. The process by which cancer cells survive and proliferate while evading anticancer drug attacks requires a more organic and interconnected signaling network. Recently, the academic community has begun to recognize that these two factors communicate closely and regulate cancer cell growth and metastasis.
Key Findings
In the tumor microenvironment, lncRNAs and m6A form a reciprocal, bidirectional regulatory circuit. m6A modification induces the binding of specific "reader" proteins, which alters the fate of lncRNAs. Specifically, the YTHDF family of reader proteins induce the degradation of target lncRNAs, while the IGF2BP family stabilizes the molecules. These methylation marks are also critical factors that determine the intracellular localization, splicing patterns, and binding affinity of lncRNAs.
Conversely, lncRNAs also act as regulators that control the m6A modification process. They directly bind to "writer" complexes that induce methylation or "eraser" complexes that remove methylation. They function as scaffolds, guides, and decoys, finely tuning the active sites and target selectivity of these enzymes. This interaction creates feedforward and feedback loops, leading to major cancer characteristics such as cancer cell proliferation, immune evasion, energy metabolism reprogramming, and the acquisition of drug resistance.
To elucidate the causal relationship of this regulatory circuit, various experimental techniques are employed, including site-directed mutagenesis, CRISPR-based gene editing, and rescue assays. In addition, m6A detection technology is also evolving. It is moving away from antibody-dependent methods such as methylated RNA immunoprecipitation sequencing (MeRIP-seq) to directly read methylation at the single-molecule level using nanopore sequencing. Recently, single-cell transcriptomics and spatial transcriptomics technologies have been combined to begin reconstructing cell-state-specific gene networks within the tumor microenvironment in a spatial manner.
Significance and Prospects
By deciphering the interaction map of the epitranscriptome and non-coding RNAs, a new path toward precision oncology has been opened. Profiling the interaction patterns of lncRNAs and m6A can be used as a biomarker to predict patient prognosis. In combination with liquid biopsy technology, which detects tumor-derived RNAs in blood or bodily fluids, it is expected that cancer can be diagnosed early and recurrence can be monitored in real time in a non-invasive manner.
The development of therapeutic agents for clinical application is also actively underway. Small molecule compounds that inhibit m6A writer enzymes and lncRNA-targeted RNA therapeutics are representative candidates. However, challenges remain in overcoming the safe delivery barrier in the human body and reducing toxicity due to off-target effects. If the complex signaling feedback in vivo is not accurately controlled, unexpected side effects may occur, so the development of precise gene delivery technology must be carried out in parallel.
BACKGROUND: Long non-coding RNAs and N6-methyladenosine RNA methylation represent two pivotal layers of gene regulation. Their extensive crosstalk forms a sophisticated bidirectional network that is fundamentally rewired in cancer. MAIN BODY: This review synthesizes current knowledge to elucidate the principles and consequences of this synergistic axis. We detail how m6A modification dictates long non-coding RNA stability, splicing, localization, and function through recruitment of distinct "reader" proteins, with one "reader" family primarily mediating decay while another promotes stabilization. Conversely, we examine how long non-coding RNAs act as scaffolds, guides, and decoys to modulate the activity and specificity of the m6A machinery, establishing powerful feedforward and feedback loops. This reciprocal regulation converges on multiple cancer hallmarks, including proliferation, metabolic reprogramming, immune evasion, stemness, and therapeutic resistance. We critically discuss experimental strategies to establish causal relationships, including site-directed mutagenesis, CRISPR-based editing, and rescue assays. We also evaluate current methodological limitations in m6A detection, from antibody-dependent approaches to emerging nanopore sequencing, and highlight how single-cell and spatial transcriptomic technologies can resolve cell-state-specific networks within the tumor microenvironment. From a translational perspective, we compare small molecule inhibitors targeting m6A "writers" with RNA-based therapies, addressing their respective delivery challenges and toxicity concerns. Finally, we outline how m6A-related long non-coding RNA signatures serve as prognostic biomarkers and liquid biopsy tools for non-invasive cancer monitoring. CONCLUSION: By integrating molecular mechanisms with clinical perspectives, this review charts a roadmap for targeting the epitranscriptomic-long non-coding RNA circuit in precision oncology.
The elucidation of this reciprocal regulatory network can be directly applied to the design of personalized therapies for refractory cancers that exhibit resistance to anticancer drugs. For example, it is possible to analyze a blood biopsy sample from a non-small cell lung cancer (NSCLC) patient who has acquired resistance to third-generation targeted therapies and confirm changes in the concentration of specific m6A-methylated lncRNAs. Based on this result, a combination of methylation inhibitors and RNA interference (RNAi) therapeutics can be administered to block the cancer cell's bypass survival pathways. The pharmaceutical industry has the opportunity to expand its new drug pipeline by converting previously difficult-to-target non-coding regions into potential drug targets.